New Late-Breaking Results from Phase 3 Trials of SKYRIZI® (risankizumab) Evaluating Long-term Effect on Skin and Joint Symptoms in Patients with Psoriatic Arthritis at Week 100

/PRNewswire/ -- AbbVie (NYSE: ABBV) announced new, long-term data analyses of KEEPsAKE 1 and 2, Phase 3 trials evaluating SKYRIZI® (risankizumab, 150 mg) in...

Related Keywords

Milan ,Lombardia ,Italy ,Sweden ,Denmark ,Copenhagen ,Køavn ,Doina Cosma Roman ,Lars Erik Kristensen ,Clin Rheumatol ,European Academy Of Dermatology ,Instagram ,Abbvie Ltd ,Linkedin ,Twitter ,Venereology Virtual Congress ,Boehringer Ingelheim ,American College Of Rheumatology ,Allergan ,Abbvie Inc ,Facebook ,University Hospital In Lund ,Parker Institute ,Clinical Development ,Exchange Commission ,Youtube ,Psoriasis Area ,Severity Index ,American College ,European Academy ,Hybrid Congress ,Global Assessment ,Fingernail Psoriasis ,Nail Psoriasis Severity Index ,Important Safety Information ,Allergan Aesthetics ,Private Securities Litigation Reform Act ,Quarterly Reports ,Active Psoriatic Arthritis ,Week Results ,Week Results From ,Venereology Virtual ,Including Patients With Inadequate Response ,Biologic Therapies ,Pract Res Clin ,Accessed August ,Study Comparing Risankizumab ,Subjects With Active Psoriatic Arthritis ,Who Have ,Inadequate Response ,Least One Disease Modifying Anti Rheumatic Drug ,Double Blind Study Comparing Risankizumab ,Biologic Therapy ,Placebo Controlled Induction Study ,Severely Active Ulcerative ,Abbvie ,